Shares of Cerus Corp. rose Tuesday as an R.W. Baird analyst upgraded his rating on the company, citing the value and potential of the Intercept blood system.
The system is used to clean bacteria, viruses, and parasites out of donated blood prior to transfusion. R.W. Baird analyst Christopher J. Raymond upgraded the stock to "Outperform" from "Neutral" and raised his price target to $5 from $3.
Shares of the Concord, Calif., company jumped 31 cents, or 13.2 percent, to $2.67 in afternoon trading. The stock has traded between 60 cents and $3.57 over the last 52 weeks.
"With signs of sustainable commercial progress in …
Комментариев нет:
Отправить комментарий